文献速递药物不良反应与药物警戒

行为科学:增强有效附加风险最小化策略开发的方法

Behavioral Science: Enhancing Our Approach to the Development of Effective Additional Risk Minimization Strategies.
PubMed 文献 · Drug Saf · 2024-04-09

本文指出附加风险最小化策略旨在影响医护人员和患者行为,但当前开发过度依赖信息提供,未充分考虑影响行为采纳与长期依从的多层因素。文章主张应用循证行为科学框架与方法,借鉴依从性、健康促进和药物利用研究证据,以提升策略质量与有效性。

要点

  • 附加风险最小化策略应超越信息提供,纳入行为科学框架。
  • 需考虑影响医护人员和患者行为的多层情境因素。
  • 依从性与健康促进证据支持行为科学方法的价值。

核心结论

  • 应用循证行为科学方法可提升附加风险最小化策略的开发质量与有效性。

研究设计与样本

  • 本文为方法学论述,基于依从性、健康促进和药物利用研究证据提出行为科学应用思路。

主要发现

  • 当前附加风险最小化策略开发过度依赖信息提供,未充分考虑影响行为采纳与长期依从的情境和多层因素。

临床怎么用

  • 在开发附加风险最小化策略时,应引入行为科学框架评估并针对影响医护人员和患者行为的多层因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Additional risk minimization strategies may be required to assure a positive benefit-risk balance for some therapeutic products associated with serious adverse drug reactions/risks of use, without which these products may be otherwise unavailable to patients. The goals of risk minimization strategies are often fundamentally to influence the behavior of healthcare professionals (HCPs) and/or patients and can include appropriate patient selection, provision of education and counselling, appropriate medication use, adverse drug reaction monitoring, and adoption of other elements to assure safe use, such as pregnancy prevention. Current approaches to additional risk minimization strategy development rely heavily on information provision, without full consideration of the contextual factors and multi-level influences on patient and HCP behaviors that impact adoption and long-term adherence to these interventions. Application of evidence-based behavioral science methods are urgently needed to improve the quality and effectiveness of these strategies. Evidence from the fields of adherence, health promotion, and drug utilization research underscores the value and necessity for using established behavioral science frameworks and methods if we are to achieve clinical safety goals for patients. The current paper aims to enhance additional risk minimization strategy development and effectiveness by considering how a behavioral science approach can be applied, drawing from evidence in understanding of engagement with pharmaceutical medicines as well as wider public health interventions for patients and HCPs.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Treacy J, Morrato EH, Horne R, et al. Behavioral Science: Enhancing Our Approach to the Development of Effective Additional Risk Minimization Strategies. Drug Saf. 2024. PMID: 38594553. doi:10.1007/s40264-024-01420-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。